Laboratory

Automate Analysis and Enhance Lab Safety with New NexaFlo™ Segmented Flow Analyzer

Retrieved on: 
Wednesday, April 3, 2024
Environmental monitoring, Potassium chloride, Health, Nutrient, Environment, Data analysis, Risk, Research, Spillage, Laboratory, KPM, Workflow, Chemistry, EPA, Safety, Ammonia, Instrumentation

, April 3, 2024 /PRNewswire/ -- Speed up analytical processes while also enhancing lab safety with a new segmented flow analyzer from KPM Analytics.

Key Points: 
  • , April 3, 2024 /PRNewswire/ -- Speed up analytical processes while also enhancing lab safety with a new segmented flow analyzer from KPM Analytics.
  • NexaFlo™ is the fourth generation of segmented flow analyzers from KPM, which has supplied thousands of consoles for laboratories across the globe.
  • One key feature of the NexaFlo™ analyzer is that it was designed to directly address lab safety.
  • For more information about NexaFlo™ segmented flow analyzers, visit the KPM Analytics product page for this new addition to our lineup: www.kpmanalytics.com/products/chemical-clinical/nexaflo-segmented-flow-a... .

Automate Analysis and Enhance Lab Safety with New NexaFlo™ Segmented Flow Analyzer

Retrieved on: 
Wednesday, April 3, 2024
Environmental monitoring, Potassium chloride, Health, Nutrient, Environment, Data analysis, Risk, Research, Spillage, Laboratory, KPM, Workflow, Chemistry, EPA, Safety, Ammonia, Instrumentation

WESTBOROUGH, Mass., April 3, 2024 /PRNewswire/ -- Speed up analytical processes while also enhancing lab safety with a new segmented flow analyzer from KPM Analytics.

Key Points: 
  • WESTBOROUGH, Mass., April 3, 2024 /PRNewswire/ -- Speed up analytical processes while also enhancing lab safety with a new segmented flow analyzer from KPM Analytics.
  • NexaFlo™ is the fourth generation of segmented flow analyzers from KPM, which has supplied thousands of consoles for laboratories across the globe.
  • One key feature of the NexaFlo™ analyzer is that it was designed to directly address lab safety.
  • For more information about NexaFlo™ segmented flow analyzers, visit the KPM Analytics product page for this new addition to our lineup: www.kpmanalytics.com/products/chemical-clinical/nexaflo-segmented-flow-a... .

Biofidelity raises $24 million in new financing to accelerate commercialization and expand product pipeline

Retrieved on: 
Wednesday, April 3, 2024
Lung cancer, LBA, Conference, Growth, NSCLC, Partnership, Patient, NGS, Biomarker, Research, Octopus Group, Laboratory, Medicine, AACR, Agilent Technologies, Pharmaceutical industry

Additionally, the new investment will enable the establishment of a dedicated manufacturing facility in the United Kingdom and drive pipeline expansion efforts across the Company's innovative technology platforms.

Key Points: 
  • Additionally, the new investment will enable the establishment of a dedicated manufacturing facility in the United Kingdom and drive pipeline expansion efforts across the Company's innovative technology platforms.
  • "This significant investment underlines the confidence of our investors in Biofidelity's unique technologies and our mission to bring the benefits of precision medicine to all patients," said Biofidelity Co-Founder and CEO Dr. Barnaby Balmforth.
  • The new funding round includes fresh commitments from current investors including Agilent Technologies, Octopus Ventures, BlueYard Capital, and Longwall Ventures.
  • "We are thrilled to continue our partnership with Biofidelity as the team embarks on the next phase of their growth and commercial expansion."

PixCell Medical Partners with Healthcare Giants Medline, Henry Schein, and Fisher Scientific to Distribute HemoScreen Point of Care CBC Analyzer Across the USA

Retrieved on: 
Wednesday, April 3, 2024
Diagnosis, Analyser, Complete blood count, Partnership, Thermo Fisher Scientific, CBC, Medline Industries, MEDLINE, Laboratory, Workflow, CCO, Health, Medical device

The partnership with Henry Schein, a global leader in healthcare solutions, will leverage the company's extensive distribution network to make the HemoScreen analyzer readily available to healthcare professionals nationwide.

Key Points: 
  • The partnership with Henry Schein, a global leader in healthcare solutions, will leverage the company's extensive distribution network to make the HemoScreen analyzer readily available to healthcare professionals nationwide.
  • Additionally, Thermo Fisher Scientific, renowned for its scientific expertise and comprehensive product offerings, will contribute to broadening the reach of the HemoScreen analyzer within the scientific research and laboratory community.
  • "We are thrilled to join forces with Henry Schein, Medline, and Thermo Fisher Scientific to bring the HemoScreen point-of-care CBC analyzer to healthcare providers and laboratories throughout the United States," said Guy Frak, CCO of PixCell Medical.
  • Through these collaborations, PixCell Medical remains dedicated to advancing healthcare delivery by making cutting-edge diagnostic technology accessible and affordable across diverse healthcare settings.

Cepheid Announces World Health Organization Prequalification of Xpert HIV-1 Qualitative Test

Retrieved on: 
Wednesday, April 3, 2024
ART, Diagnosis, Mother, Survival, EVP, Cepheid (company), HIV, Viral load, Seroconversion, Cepheid variable, Hospital, Anxiety, Laboratory, Science, World Health Organization, Safety, WHO, Vaccine

SUNNYVALE, Calif., April 3, 2024 /PRNewswire/ -- Cepheid today announced that Xpert® HIV-1 Qual XC has been awarded World Health Organization (WHO) prequalification. Inclusion on the prequalification list signifies that Xpert HIV-1 Qual XC meets WHO's stringent performance, quality, safety and reliability standards. Xpert HIV-1 Qual XC (extended coverage) is an in vitro nucleic acid amplification test for the qualitative detection of HIV-1 total nucleic acids directly from human dried blood spots and capillary or venous whole blood specimens.

Key Points: 
  • SUNNYVALE, Calif., April 3, 2024 /PRNewswire/ -- Cepheid today announced that Xpert® HIV-1 Qual XC has been awarded World Health Organization (WHO) prequalification.
  • Inclusion on the prequalification list signifies that Xpert HIV-1 Qual XC meets WHO's stringent performance, quality, safety and reliability standards.
  • The test has been cleared for use in early diagnosis of infants, adolescents, and adults at the point of care and in laboratories.
  • Xpert HIV-1 Qual XC is part of a comprehensive portfolio of WHO pre-qualified Xpert tests available internationally, including Xpert HIV-1 Viral Load, Xpert HBV Viral load, Xpert HCV Viral Load, Xpert HCV VL Fingerstick, and Xpert HPV, and WHO endorsed Xpert MTB/RIF Ultra and Xpert MTB/XDR.

Lung Cancer Research Foundation Names 2024 Evening of Innovation Gala Honoree

Retrieved on: 
Tuesday, April 2, 2024
Lung cancer, Innovation, Mentorship, Metropolitan Club, Patient, Research, Hope, Laboratory, Medicine, Nausea, LCMC, Metropolitan, Vomiting, Physician, Person, Pharmaceutical industry

NEW YORK, April 2, 2024 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF) is pleased to announce Dr. Mark G. Kris as its honoree for the 3rd annual Evening of Innovation Gala, which will be held on September 24, 2024 at the Metropolitan Club in Manhattan. Members of LCRF's Board of Directors and Gala Committee are committed to showcasing LCRF's impact through recognition of an individual whose support of the organization and the field of lung cancer research is unparalleled, and someone who exemplifies the spirit of LCRF to improve the lives of persons with lung cancers through research.

Key Points: 
  • Foundation Honors Contributions of Dr. Mark G. Kris
    NEW YORK, April 2, 2024 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF) is pleased to announce Dr. Mark G. Kris as its honoree for the 3rd annual Evening of Innovation Gala, which will be held on September 24, 2024 at the Metropolitan Club in Manhattan.
  • As a thoracic oncologist at Memorial Sloan Kettering, Dr. Kris's clinical and research accomplishments over the last four decades have transformed lung cancer care both nationally and internationally.
  • Dr. Kris's impact at the Lung Cancer Research Foundation spans decades, beginning with an advisory role in Joan's Legacy.
  • The 2024 Evening of Innovation Gala will take place at 6 pm on Tuesday, September 24, 2024, at the Metropolitan Club in New York City.

Rady Children's Appoints Praveen Raju, MD, PhD, as the Nathan Gordon Chair and Medical Director of Neuro-Oncology Program

Retrieved on: 
Tuesday, April 2, 2024
Research, Diagnosis, Boston Children's Hospital, Brain, Health, Growth, Neurology, MSTP, Memory, Genetics, SAN, Patient, UC, Cancer, Medulloblastoma, Child, University, Neurosurgery, Doctor of Philosophy, Neuro, MD, Molecular biology, NIH, Laboratory, Pediatric neurosurgery, Neoplasm, Infant, Nathan Gordon, Hospital, Spinal cord, Pediatrics, Neuro-Oncology (journal), Medical director, Genetic distance, Nursing

At Rady Children's, Dr. Raju has also been named the Nathan Gordon Chair in Neuro-Oncology, established in 2021 to honor the memory of Nathan Gordon, who was diagnosed with a rare tumor in his spinal cord when he was just 15 months old.

Key Points: 
  • At Rady Children's, Dr. Raju has also been named the Nathan Gordon Chair in Neuro-Oncology, established in 2021 to honor the memory of Nathan Gordon, who was diagnosed with a rare tumor in his spinal cord when he was just 15 months old.
  • As part of Rady Children's nationally recognized care team, Dr. Raju will spearhead the growth of the Neuro-Oncology Program and advance research efforts on pediatric brain and spinal tumors.
  • By incorporating subspecialty expertise, Dr. Raju aims to address different forms of pediatric brain and spinal tumors.
  • By incorporating subspecialty expertise into the Neuro-Oncology Program, Dr. Raju aims to address the different forms and distinct molecular subtypes of pediatric brain and spinal tumors.

Quest Diagnostics and Broad Clinical Labs to Evaluate Whole Genome Sequencing as First-Line Genetic Test for Developmental Delay

Retrieved on: 
Tuesday, April 2, 2024
Diagnosis, WGS, Disease, FACMG, Broad Institute, Genetic testing, Fragile X syndrome, Massachusetts General Hospital, MIT, Harvard University, CMA, Patient, Medical genetics, Research, Mortality, Laboratory, DGX, Senior, Genome, American College, Saliva, Intellectual disability, Hospital, Whole genome sequencing, ACMG, Blood, Quest Diagnostics, Antibiotics

SECAUCUS, N.J., April 2, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and Broad Clinical Labs, the world expert in whole genome sequencing (WGS), today announced a research collaboration designed to demonstrate the clinical value of WGS as a first-line genetic test for postnatal diagnosis of developmental delay disorders.

Key Points: 
  • "We are delighted to bring the experience and expertise of Broad Clinical Labs to this innovative collaboration with Quest.
  • "This type of collaboration between commercial laboratories and research institutions is vital to advance the field of genetic testing and increase utility and economic value."
  • While the ACMG recommends WGS for first-line genetic testing for intellectual disability and developmental delay, some providers continue to follow prior guidelines that recommend chromosomal microarray (CMA) as a first-line test.
  • Broad Clinical Labs is a leader in human whole genome sequencing, having sequenced over 600,000 genomes in service of its mission to accelerate the understanding and diagnosis of human disease.

ThinkCyte advances biopharma phenotypic drug discovery programs with publication and presentation milestones

Retrieved on: 
Monday, April 1, 2024
University, Automation, Gene, Drug discovery, Cell Press, DNA, Artificial intelligence, SLAS, Society, Laboratory, CRISPR, Cell

TOKYO, April 1, 2024 /PRNewswire/ -- ThinkCyte today announced the publication of a paper in the March issue of Cell Reports Methods on a new method for high-throughput drug discovery.

Key Points: 
  • TOKYO, April 1, 2024 /PRNewswire/ -- ThinkCyte today announced the publication of a paper in the March issue of Cell Reports Methods on a new method for high-throughput drug discovery.
  • The new approach allows for not only faster drug screening, but also opens the door to use a host of new morphology-driven phenotypes in drug discovery campaigns.
  • In December, the company was also profiled in a special edition of Cell Press highlighting the emerging uses of AI in drug discovery screening.
  • "Our biopharma customers are looking to integrate new technologies to expand their phenotypic drug screening programs," said Janette Phi, Chief Business Officer at ThinkCyte.

On Target Laboratories Founder Philip Low Receives Legacy Award from the American Lung Association

Retrieved on: 
Monday, April 1, 2024
Lung cancer, ALA, Organization, Innovation, Biotechnology, Disease, Cancer, Health, Patient, Legacy Award, Research, Laboratory, Surgeon, CVS Health, Prognosis, Purdue University

WEST LAFAYETTE, Ind., April 1, 2024 /PRNewswire/ -- Dr. Philip S. Low, Founder and Chief Science Officer of On Target Laboratories, Inc., will receive the Indiana American Lung Association's (ALA) Legacy Award for his lifetime and innovative work on targeted molecules. The annual Indiana ALA Legacy Award is given to individuals or organizations whose accomplishments are contributing to ending lung cancer and will be presented to Dr. Low at the ALA's "Evening of Promise Gala" in Indianapolis on Saturday, April 13. 

Key Points: 
  • Founder and Purdue University researcher Philip Low to be recognized for his invention of CYTALUX, a fluorescent targeted molecule that illuminates lung cancer cells during surgery
    WEST LAFAYETTE, Ind., April 1, 2024 /PRNewswire/ -- Dr. Philip S. Low, Founder and Chief Science Officer of On Target Laboratories, Inc., will receive the Indiana American Lung Association's (ALA) Legacy Award for his lifetime and innovative work on targeted molecules.
  • Dr. Low invented CYTALUX as part of his founding work with On Target Laboratories, a privately held biotechnology company whose mission is to illuminate cancer so it can be removed completely.
  • "We are proud that our Founder and Chief Science Officer, Dr. Low, is being celebrated for his dedication and innovative work to illuminate cancer during surgery," said Ben Lundgren, Chief Executive Officer of On Target Laboratories.
  • "I am honored to be receiving this year's Legacy Award from the Indiana American Lung Association," said Dr. Low.